Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
OBJECTIVE: Long-standing evidence indicates that Alzheimer's disease patients with behavioral symptoms have a worse prognosis and a more rapid disease progression. The current retrospective analysis evaluated the efficacy and safety of memantine in a subpopulation of patients with Alzheimer...
Κύριοι συγγραφείς: | Wilcock, G, Ballard, C, Cooper, J, Loft, H |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
2008
|
Παρόμοια τεκμήρια
-
Treatment benefits of memantine in moderately severe to severe Alzheimer's disease patients with behavioural symptoms
ανά: Wilcock, G, κ.ά.
Έκδοση: (2006) -
Donepezil and memantine for moderate-to-severe Alzheimer's disease
ανά: Howard, R, κ.ά.
Έκδοση: (2012) -
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.
ανά: Jones, R, κ.ά.
Έκδοση: (2009) -
Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis
ανά: Dominik Glinz, κ.ά.
Έκδοση: (2019-06-01) -
Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer’s Disease: A Review of Clinical Trials
ανά: Ivana Molino, κ.ά.
Έκδοση: (2013-01-01)